- Home
- UPXI vs NRXP Comparison
UPXI vs NRXP Comparison
Compare UPXI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UPXI | NRXP |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 62.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UPXI | NRXP |
|---|---|---|
| Price | $0.72 | $1.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.00 | ★ $30.67 |
| AVG Volume (30 Days) | ★ 4.0M | 569.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $141.57 | N/A |
| Revenue Next Year | $14.83 | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $1.58 |
| 52 Week High | $22.57 | $3.84 |
Technical Indicators
Market Signals| Indicator | UPXI | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 20.89 | 40.74 |
| Support Level | $0.71 | $1.70 |
| Resistance Level | $2.05 | $2.00 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 1.09 | 27.78 |
Price Performance
Historical ComparisonAbout UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.